Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15429528 | 0.85 | CHRNB2 (0.56) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL30954573 | 0.85 | CHRNB2 (0.56) | CHRNB2CHRNA4KMT2A | |
| SCHEMBL13113159 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA4KMT2ACCNCCDK8 | |
| SCHEMBL28467746 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4KMT2ACCNCCDK8 | |
| SCHEMBL15426554 | 0.81 | KMT2A (0.54) | CHRNB2CHRNA4KMT2ACCNCCDK8 | |
| SCHEMBL15429530 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4KMT2ADRD2DRD3 | |
| SCHEMBL10764946 | 0.79 | CHRNB2 (0.52) | CHRNB2CHRNA4KMT2AFAAHLMNA | |
| SCHEMBL8278956 | 0.78 | MTNR1A (0.59) | KMT2ACYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL10458730 | 0.78 | TBXAS1 (0.59) | CHRNB2CHRNA4 | |
| Bicarbonate SCHEMBL19876805 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4KMT2ACCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115070-B2 | Process for preparing acrylic acid from ethylene oxide and carbon monoxide | BASF SE (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20140018570-A1 | PROCESS FOR PREPARING ACRYLIC ACID FROM ETHYLENE OXIDE AND CARBON MONOXIDE | BASF SE (DE) | 2014-01-16 | — | — | US | disclosed |
| EP-1171127-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6627648-B1 | Relevant nicotinic receptor subtypes to any significant degree. central nervous system disorders, are treated by administering to a patient in need thereof amine derivatives | TARGACEPT, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6489349-B1 | TREATING AN AUTOIMMUNE DISORDER WITH AN ALKYLAMINE SUBSTITUTED PYRIDINE | TARGACEPT, INC. | 2002-12-03 | — | — | US | disclosed |
| US-6441007-B1 | TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH PYRIDYLOXYLALKYLAMINES AND PHENOXYALKYLAMINES | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6441006-B2 | NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1185513-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1171127-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATIVES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | Targacept, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-10-18 | — | — | US | disclosed |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. | 2001-08-16 | — | — | US | disclosed |
| EP-1068186-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000071520-A2 | ARYL SUBSTITUTED ALKYLAMINES CAPABLE OF ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999051216-A2 | 3-PYRIDYLOXYALKYLAMINE OR ARYLOXYALKYLAMINE DERIVATIVES AS CHOLINERGIC AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018570-A1 | PROCESS FOR PREPARING ACRYLIC ACID FROM ETHYLENE OXIDE AND CARBON MONOXIDE | HPD, HAAO, HAO2 | CHRNB2 2148/4885CHRNA4 1949/4885KMT2A 2773/4885 |
| US-20010031771-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, TPMT, HTR7 | CHRNB2 98/4885CHRNA4 32/4885KMT2A 810/4885 |
| US-20010014691-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PNMT, HNMT, CHRM3 | CHRNB2 32/4885CHRNA4 34/4885KMT2A 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.